echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui's clinical application for 3 new drugs has been accepted

    Hengrui's clinical application for 3 new drugs has been accepted

    • Last Update: 2021-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    On September 23, the CDE official website showed that the clinical trial applications of Hengrui's three drugs were accepted, namely famitinib malate capsules, SHR-1802, and carrelizumab


    Carrelizumab is a humanized anti-PD-1 monoclonal antibody that can bind to human PD-1 receptors and block the PD-1/PD-L1 pathway, restore the body’s anti-tumor immunity, thereby forming Fundamentals of Cancer Immunotherapy


    Famitinib Malate Capsules is a small molecule multi-target tyrosine kinase inhibitor independently developed by Hengrui.


    SHR-1802 is a monoclonal antibody targeting lymphocyte activation gene 3 protein (LAG3)


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.